Drug Profile
Nabiximols - GW Pharmaceuticals
Alternative Names: Cannabidiol/tetrahydrocannabinol; CBD/THC; CBD:THC; Delta-9-tetrahydrocannabinol/cannabidiol; Delta-9-THC/cannabidiol; Dronabinol/cannabidiol; GW 1000; GW-1000-02; JZP-378; Medicinal cannabis - GW Pharmaceuticals; Nabidiolex®/Tetranabinex®; Sativex; Tetrahydrocannabinol/cannabidiol; THC/CBD; THC:CBDLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GW Pharmaceuticals
- Developer Almirall S.A.; GW Pharmaceuticals; Neopharm Ltd; Novartis; Otsuka Pharmaceutical
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antidementias; Antiemetics; Antiepileptic drugs; Antihyperglycaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Appetite stimulants; Cannabinoids; Chromans; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Non-opioid analgesics; Obesity therapies; Phytotherapies; Skin disorder therapies
- Mechanism of Action Antioxidants; Cannabinoid receptor agonists; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cancer pain; Muscle spasticity; Neuropathic pain
- Discontinued Bladder dysfunction; Glioblastoma; Post-traumatic stress disorders; Stomatitis
Most Recent Events
- 24 Mar 2023 Jazz Pharmaceuticals terminates the phase III RELEASE MSS3 trial for Muscle spasticity in Czech Republic, Poland, Romania, United Kingdom and USA based on a business decision by the sponsor (EudraCT2019-002623-14) (NCT04203498)
- 27 Feb 2023 GW Pharmaceuticals completes the phase III RELEASE MSS3 trial for Muscle spasticity in Czech Republic, Poland, Romania, United Kingdom and USA (EudraCT2019-002623-14) (NCT04203498)
- 11 Nov 2022 Jazz Pharmaceuticals terminates a phase III RELEASE MSS5 trial in Muscle spasticity related to Multiple sclerosis in Czech Republic, Spain, Poland, USA and United Kingdom (Buccal, Spray) based on a business decision by the Sponsor (EudraCT2020-003271-18) (NCT04984278)